Nimrit Palan, Mumbai university
One of the most prevalent types of cancer in dogs is lymphoma. It is made up of immune system cells called lymphocytes that circulate through the bloodstream. As a result, lymphoma is often seen as a systemic disease that requires systemic treatment. Dogs with lymphoma have a life expectancy of 1-2 months if they are not treated. With treatment, roughly 80%–90% of dogs with lymphoma have a complete remission, with an average lifespan of 12–14 months in dogs who are in good health.
Lymphoma in dogs will usually kill them within 3 to 4 weeks if they are not treated. Usually, dogs with lymphoma only live for two to three months if they are not treated. Swelling or enlarging lymph nodes, notably in the neck, back of the jaw, and behind the knees, appetite loss is common, lethargy, loss of weight, thirst, and urination have increased, fever, breathing problems. A sample from a lymph node is routinely taken, either by fine-needle aspiration or biopsy, to confirm the diagnosis of lymphoma. A biopsy is the most accurate approach to diagnose lymphoma.
TREATMENT OF LYMPHOMA IN DOGS BY TANOVEA DRUGS
Tanovea is successful in the treatment of non-lymphoma Hodgkin’s (NHL), canine cutaneous T-cell lymphoma, spontaneous canine multiple myeloma, naive canine multicentric lymphoma, and relapsed canine B-cell lymphoma in dogs and is approved by FDA (Food and Drug Administration). Tanovea® (formerly GS-9219, now VDC-1101, generic name: rabacfosadine) is a PMEG [9-(2-phosphonylmethoxyethyl) guanine] pro-prodrug or “double” prodrug that has been conditionally licensed by the US FDA (Food and Drug Administration) for the treatment of lymphoma in dogs.
HOW TANOVEA IS SUPPLIED?
TANOVEA® is packaged in a carton and comes in a 3 mL amber Type I glass vial with a rubber stopper, aluminum over-seal, and plastic flip-off lid. The succinate salt of rabacfosadine is 16.4 mg each vial.
EFFECTIVENESS OF TANOVEA
In one adequate and well-controlled clinical field research, the efficacy of TANOVEA® was proven. The study included 158 dogs of any breed (excluding West Highland White Terrier) or sex who had been diagnosed with multicentric lymphoma with at least one detectable peripheral lymph node. When comparing the TANOVEA® group to the placebo group, the efficacy analysis revealed a statistically significant improvement in progression-free survival (PFS).
ADVERSE REACTIONS OF TANOVEA
Field safety was assessed in 120 dogs given TANOVEA® and 38 dogs given a placebo. Diarrhea, decreased appetite, vomiting, fatigue, weight loss, and neutropenia were the most common side effects. Both groups experienced diarrhea, decreased appetite, vomiting, fatigue, and weight loss. In the TANOVEA® group, the incidence was greater, and there were more Grade 1 case. In comparison to the placebo group, there were 2 and 3 adverse events, respectively.
APPROVAL OF TANOVEA
Tanovea is the first novel animal medicine for dogs to receive full FDA approval after being conditionally approved. After receiving conditional approval under statutory provisions related to drugs intended for uncommon diseases or conditions in major animal species (minor uses) or use in minor species of animals under the FDA’s Minor Use and Minor Species (MUMS) program, Tanovea was approved using the new animal drug approval process. While canine lymphoma affects fewer than 70,000 canines in the United States each year, it accounts for up to 24% of all dog malignancies, making it one of the most serious. For the first time, dog owners can be assured that their pet’s treatment has satisfied all of the FDA’s requirements for effectiveness in canines.
Also read: Romanesco cauliflower & its spiraling fractal shape
REFERENCES:
- FDA Grants First Full Approval for Treatment of Lymphoma in Dogs- https://www.fda.gov/news-events/press-announcements/fda-grants-first-full-approval-treatment-lymphoma-dogs
- De Clercq, E. (2018). Tanovea® for the treatment of lymphoma in dogs. Biochemical Pharmacology, 154, 265–269. https://doi.org/10.1016/j.bcp.2018.05.010
- The Corrosion Prediction from the Corrosion Product Performance
- Nitrogen Resilience in Waterlogged Soybean plants
- Cell Senescence in Type II Diabetes: Therapeutic Potential
- Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
- AI Literacy in Early Childhood Education: Challenges and Opportunities
Congratulations Nimrit !!